Advancing Personalized, Next-Generation Therapeutics to Redefine Metabolic Quality to Accelerate the Shift From Acute Weight Loss to Sustainable Disease Modification by Demonstrating Durable, Best-in-Class Therapeutic Impact
Welcome to the 4th Obesity & Weight Loss Drug Development Summit - the definitive industry-forum dedicated to redefining the standards of metabolic medicine by mastering precision treatment, preserving functional health, and navigating the high-stakes transition to next-generation oral and multi-agonist therapies.
The obesity therapeutics market has entered a radical transformation. Driven by the unprecedented success of first-generation incretins, the landscape has reached a critical juncture where "simple weight loss" is no longer enough to win. As we move through 2026, the industry is under intense pressure to move beyond BMI-centric endpoints and unlock new levels of quality, targeting the 40% of adults globally who require more than a one-size-fits-all approach. The race is now on to decouple adipose reduction from skeletal muscle atrophy and secure long-term adherence through needle-free, scalable solutions that promise to transform chronic disease management forever.
The 4th Obesity & Weight Loss Drug Development Summit stands as the essential global forum for experts dedicated to accelerating this vital progress. This year, we are diving deep into the game-changing potential of multi-targeted portfolios, novel biological pathways and new modalities for a precision medicine approach, alongside the "Oral-First" revolution.
Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly, and Merck & Co., as well as innovative biotechs such as Veru Inc., Canary Cure, and Metsera, who will share their ground-breaking research on preserving lean mass and preventing post-treatment weight regain.
Don't miss this pivotal opportunity to network with 120+ leading experts in the field of advanced obesity therapeutics. Forge crucial collaborations and be part of the solution that will define the 2026 pipeline.
High quality of speakers and collegial atmosphere. Opportunity for all attendees to contribute. Multi-disciplinary approach of pharmacy, biotech, CROs, RWE and imaging all in one.
Associate Vice President, Eli Lilly
Highly relevant talks on the latest clinical use cases and development paths for obesity therapies. Senior decision makers from top tier pharmas. CROs offering support services specific to development of therapies in this field.
CEO, Nuanced Health
Pertinent topics, good speakers, terrific opportunity to network, several useful contacts resulted.
Director, Medical Merger & Acquisition, Scientific Advisory, Novo Nordisk
Key Topics
Explore the Full Event Guide
- Access 16+ hours of data-driven content and deep dive into two full days of scientific programming, featuring high-level case studies on triple-agonists, mitochondrial metabolism, and next-generation oral small molecules to define the 2026 obesity pipeline
- Learn more about 2 focused, practical workshops at the pre-conference day featuring hands-on sessions led by Veru Inc. and Canary Cure
- See the world-class faculty including senior leaders from Novo Nordisk, Eli Lilly, and Merck & Co., SixPeaks Bio, Metsera and Syntis Bio
- Find out how you can forge high-value partnerships with senior leaders during 6+ hours of networking
- Explore 7 core strategic pillars from optimizing multi-targeted portfolios to prioritizing muscle quality and functional longevity
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.